Table 4 Cox regression analysis estimated prognostic value by hazard ratios (HR) and 95% CI* for relapse-free survival and disease-specific survival
From: Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen
Variable | Relapse-free survival | Disease-specific survival | ||||
|---|---|---|---|---|---|---|
P** | HR | 95% CI | P** | HR | 95% CI | |
PTEN (per score point) | 0.001 | 0.54 | 0.373–0.785 | 0.218 | 0.775 | 0.517–1.162 |
Age (per year) | 0.204 | 1.02 | 0.992–1.039 | 0.642 | 1.006 | 0.981–1.032 |
Stage | 0.004 | 2.05 | 1.263–3.336 | 0.032 | 1.830 | 1.055–3.175 |
Axillary LN metastases (none vs 1–3 vs ≥4) | 0.032 | 1.61 | 1.043–2.492 | 0.237 | 1.374 | 0.811–2.328 |
Tumor size (per cm) | 0.96 | 1.01 | 0.739–1.376 | 0.909 | 1.022 | 0.701–1.490 |
Tumor grade (per point) | 0.80 | 0.94 | 0.593–1.498 | 0.886 | 0.962 | 0.566–1.635 |
ER-α (per score point) | 0.46 | 1.11 | 0.841–1.469 | 0.483 | 1.114 | 0.824–1.507 |
PR (per score point) | 0.74 | 1.05 | 0.810–1.348 | 0.196 | 0.826 | 0.618–1.104 |
Her-2 (per score point) | 0.04 | 1.23 | 1.008–1.502 | 0.309 | 1.127 | 0.895–1.420 |
